Introduction {#S1}
============

Lung cancer, considered to be a highly prevalent type of cancer, is a leading cause of cancer-related mortality worldwide, resulting in 1.6 million deaths each year with poor 5-year survival rate of about 4--17% ([@B27]; [@B1]). Lung cancer is classified as follows: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), accounting for approximately 20 and 80% of all lung cancer cases, respectively ([@B58]). NSCLC is a complex systems disease with dysfunctions on multiple pathways and multiple molecular levels ([@B30], [@B32]; [@B41]; [@B85]; [@B12]; [@B46]). It can also be typically divided into three main subtypes, lung adenocarcinoma (LUAD), squamous cell lung carcinoma (SCLC), and large cell cancer (LCC), according to standard pathology methods ([@B66]; [@B71]; [@B26]). Compared with squamous lung cancer, adenocarcinoma was associated with better prognosis. Despite the advances in diagnostic and therapeutic technology, lung cancer remains a serious global public health concern.

For a long time, the treatment of NSCLC has been mostly guided by tumor stage, and there has been no significant difference between the therapy strategy of LUAD and SCLC. Most lung cancers are usually diagnosed at an advanced stage and are treated primarily with systemic chemotherapy, typically with platinum-based regimens ([@B5]). Recent progress in characterization of NSCLC by molecular typing, especially in adenocarcinomas of the lung, have brought new investigation of therapeutic agents that target dominant oncogenic mutations, such as epidermal growth factor receptor (EGFR)-targeted therapies, which have showed improved response rates in patients with NSCLC ([@B65]).

Currently, progress in molecular biology of lung cancer has resulted in the identification of multiple potential biomarkers that may be related to the clinical management of NSCLC patients. In recent years, with the emergence of next-generation sequencing technologies, important molecular differences between LUAD and SCLC are increasingly identified, indicating that targeted therapy will be more and more histologically specific in the future ([@B36]; [@B69]; [@B42]). Several studies have identified multiple gene expression subtypes that differ in prognosis, genomic alterations, clinical characteristics, including tumor differentiation, stage-specific survival, underlying drivers, and potential responses to treatment within LUAD and SCLC ([@B79]; [@B73]; [@B50]). For example, LUAD patients that harbor EGFR, ALK, ROS1, or BRAF mutations were discovered to benefit the most ([@B77]; [@B26]). Targeted therapies for gene abnormalities of HER2, MET, RET, and NTRK1 appear to be an effective approach to treat LUAD ([@B17]; [@B55]). SCLC shows different mutation spectrum from that of adenocarcinoma, and the mutation targeted therapy for SCLC has not been thoroughly studied to obtain approved treatment ([@B7]; [@B67]).

A series of imaging studies suggested that NSCLC may progress rapidly between occurrence and primary treatment ([@B37]). Therefore, it is necessary for clinicians to identify between these two subtypes of NSCLC in a convenient and rapid way. With the improvement of the above clinical and molecular levels, growing evidences have shown that immunohistochemistry (IHC) is an effective tool for differentiating adenocarcinoma from squamous cell carcinoma ([@B3]; [@B78]).

It is reported that the formation and development of lung cancer are related to the accumulation of permanent genetic changes and dynamic epigenetic changes. Therefore, enhancing our understanding of tumor biology and gene expression profiles will be critical for cancer treatment and diagnosis. In this study, an integrative analysis of lung cancer methylation data and gene expression data was performed, and mixed features were also screened out for analysis.

Materials and Methods {#S2}
=====================

The Joint Methylation and Expression Profiles of Lung Cancer Patients {#S2.SS1}
---------------------------------------------------------------------

The methylation and gene expression profiles of lung cancer patients were obtained from GEO (Gene Expression Omnibus)^[1](#footnote1){ref-type="fn"}^. The data were originally generated by [@B34]. They used the data to cluster the patients into five groups, and these groups showed different overall survival ([@B34]). We were more interested in how the methylation and expression differ from well-known subtypes, especially LUAD and SCLC. Therefore, we analyzed the 77 LUAD and 22 SCLC patients who had both methylation and expression data.

The methylation profiles were measured with Illumina HumanMethylation450 BeadChip while the gene expression profiles were measured with Illumina HumanHT-12 V4.0 expression BeadChip. The probe expression levels were averaged onto 20,178 genes. The 354,251 methylation sites within genes were analyzed. Therefore, each patient was represented with 20,178 genes and 354,251 methylation sites.

Screen for the Relevant Methylation and Expression Features {#S2.SS2}
-----------------------------------------------------------

Since the number of methylation and expression features was very large, it was difficult to analyze directly. We applied the Boruta method ([@B39]) to screen the combined data and identify the relevant methylation and expression features. The Boruta method was based on random forest classification, and the relevance of features to sample classes was measured by the ensemble of the random forest classifier's stochasticity.

Evaluate the Importance of Relevant Methylation and Expression Features {#S2.SS3}
-----------------------------------------------------------------------

After the irrelevant features were removed, the relevant methylation and expression features were ranked based on their importance evaluated with MCFS (Monte Carlo Feature Selection) ([@B18]). The MCFS was a widely used method to rank features based on classification trees ([@B13], [@B14]; [@B61], [@B59],[@B60]; [@B44]). First, for the d features, we selected s subsets and each subset included m features (m was much smaller than d). Then, for each subset, t trees were constructed. Based on the s × t trees, we can estimate a feature's importance by considering how many times it appeared in these trees and how well it performed in these trees as a node. By comparing the permutation results, the significance of features was evaluated.

Perdition Performance of the Mixed Methylation and Expression Signature {#S2.SS4}
-----------------------------------------------------------------------

The MCFS can find the significant top-ranking features by comparing with permutations. To objectively evaluate the significant top-ranking features' prediction performance, we performed LOOCV (Leave One Out Cross Validation) using SVM (Support Vector Machine) classifier ([@B43]; [@B70]; [@B59]). Each time, one sample was chosen as test samples and all other samples were used to train the SVM predictor. After all samples were tested once, we compared the actual sample classes with predicted sample classes and calculated the sensitivity, specificity, accuracy, and Mathew's correlation coefficient (MCC) based on the confusion matrix ([@B31], [@B29]; [@B8]).

Results and Discussion {#S3}
======================

Rank the Methylation and Expression Features {#S3.SS1}
--------------------------------------------

The methylation and gene expression data were combined and, therefore, each lung cancer patient was represented with mixed methylation and gene expression features. The number of mixed features (20,178 gene expression features and 354,251 methylation features) was too large to conduct sophisticated statistical analysis. So, we removed irrelevant features using the Boruta method ([@B39]). At last, 711 relevant features were remained.

Then, these 711 Boruta selected features were further ranked with the MCFS method ([@B18]). As a classification tree-based ensemble learning algorithm, MCFS can rank the features based on how many times and how much it contributed to the sample classification in s × t trees. By comparing with permutation results, it can evaluate the significance of features.

Identify the Methylation and Expression Signature {#S3.SS2}
-------------------------------------------------

The 136 significant top-ranking features were identified using the latest dmLab version 2.3.0 software downloaded from^[2](#footnote2){ref-type="fn"}^ with default parameters. These 136 methylation and expression signatures are given in [Table 1](#T1){ref-type="table"}.

###### 

The 136 methylation and gene expression signature identified with the MCFS method.

  **Rank**   **Feature**   **Rank**   **Feature**   **Rank**   **Feature**   **Rank**   **Feature**
  ---------- ------------- ---------- ------------- ---------- ------------- ---------- -------------
  1          DSC3          35         cg08796240    69         cg14487292    103        cg08621277
  2          KRT5          36         cg08198430    70         cg03545620    104        cg13387113
  3          cg02194717    37         cg10969178    71         DSG3          105        S1PR5
  4          cg17814481    38         cg07838427    72         cg10991454    106        cg14769121
  5          cg00415665    39         cg15958289    73         ANXA8L1       107        cg25634000
  6          cg04432660    40         cg19445207    74         cg18736431    108        cg07417666
  7          cg12932675    41         DLX5          75         cg14108894    109        cg18383680
  8          cg13715502    42         cg26117023    76         cg17775621    110        cg11640015
  9          cg08436756    43         cg16148454    77         cg15221831    111        cg02328660
  10         cg02771299    44         cg13089599    78         cg26150462    112        cg08379517
  11         cg06555468    45         cg00180559    79         cg11288202    113        cg04778236
  12         cg13626676    46         cg21845794    80         cg27623451    114        cg11416243
  13         KRT6C         47         cg26819757    81         cg02459569    115        cg18368125
  14         cg01397507    48         cg03782130    82         cg24228306    116        cg09853371
  15         SPRR2A        49         cg17005319    83         RORC          117        cg16260888
  16         cg23613253    50         cg26795540    84         cg07538160    118        cg10842126
  17         cg24235613    51         cg17957094    85         cg12448539    119        cg17094593
  18         cg16969274    52         cg17543218    86         cg08774902    120        cg15335334
  19         FAT2          53         cg13522118    87         cg04488647    121        KRT17
  20         cg02579706    54         cg26431815    88         cg08190615    122        RFC4
  21         TMEM63A       55         cg06332339    89         cg09470758    123        cg27009392
  22         cg07568117    56         cg19883066    90         cg21922731    124        TP63
  23         KRT6A         57         cg21013395    91         cg20197694    125        cg08327518
  24         cg25922471    58         cg19526267    92         ACSL5         126        cg05800082
  25         cg23628350    59         cg02634861    93         KRT6B         127        cg05128003
  26         cg19032799    60         cg20803931    94         RAE1          128        cg04926361
  27         cg04703476    61         cg05351785    95         cg24083274    129        cg01943337
  28         cg01176141    62         cg21936454    96         cg23037777    130        cg06520450
  29         cg12788467    63         cg03361585    97         cg07112556    131        cg15441535
  30         cg24211826    64         cg20637223    98         cg26807301    132        cg25521254
  31         MUC1          65         ANXA8         99         HNF1B         133        cg21176488
  32         FMO5          66         cg15247247    100        cg18771553    134        cg05267427
  33         cg06200607    67         cg06411879    101        cg18720506    135        cg05575304
  34         VSNL1         68         cg10720966    102        cg04345366    136        cg20544605

It can be seen that within these 136 signature features, there were 113 methylation features and 23 gene expression features. The annotations of the 113 methylation features based on GPL13534^[3](#footnote3){ref-type="fn"}^ are provided in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}. We plotted the heatmaps of LUAD and SCLC lung cancer patients with 113 methylation features and 23 gene expression features in [Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, respectively. Both the 113 methylation features and 23 gene expression features can successfully group almost all samples with only three misclassified SCLC samples. They did not show difference on cluster results.

![The heatmap of LUAD and SCLC lung cancer patients with 113 methylation features. Almost all samples were correctly clustered using the 113 methylation features and only three SCLC samples were misclassified.](fbioe-08-00003-g001){#F1}

![The heatmap of LUAD and SCLC lung cancer patients with 23 gene expression features. Almost all samples were correctly clustered using the 23 gene expression features and only three SCLC samples were misclassified.](fbioe-08-00003-g002){#F2}

To more objectively and carefully compare the performance of the 113 methylation features and 23 gene expression features, we conducted LOOCV with SVM classifier. The LOOCV prediction performances of the 136 mixed features, 113 methylation features and 23 gene expression features are listed in [Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}. It can be seen that the prediction results of 113 methylation features were the same as the 136 mixed features and better than the 23 gene expression features. The 23 gene expression features had one more misclassified SCLC samples. It seemed that methylation had better performance.

###### 

The confusion matrix using 136 mixed methylation and gene expression features.

                             **Actual LUAD**                                                       **Actual SCLC**
  -------------------------- --------------------------------------------------------------------- -----------------
  Predicted LUAD             77                                                                    2
  Predicted SCLC             0                                                                     20
  Performance Measurements   Sensitivity: 1.000, specificity: 0.909, accuracy: 0.980, MCC: 0.941   

###### 

The confusion matrix using 113 methylation features.

                             **Actual LUAD**                                                       **Actual SCLC**
  -------------------------- --------------------------------------------------------------------- -----------------
  Predicted LUAD             77                                                                    2
  Predicted SCLC             0                                                                     20
  Performance Measurements   Sensitivity: 1.000, specificity: 0.909, accuracy: 0.980, MCC: 0.941   

###### 

The confusion matrix using 23 gene expression features.

                             **Actual LUAD**                                                       **Actual SCLC**
  -------------------------- --------------------------------------------------------------------- -----------------
  Predicted LUAD             77                                                                    3
  Predicted SCLC             0                                                                     19
  Performance Measurements   Sensitivity: 1.000, specificity: 0.864, accuracy: 0.970, MCC: 0.912   

Comparison With CNV Signature {#S3.SS3}
-----------------------------

Comparing with the 136 LUAD and SQCLC CNV signatures identified by [@B42], we found that the methylated genes HORMAD2, KLHL3, LPP, and PTPN3 are also CNAs genes. HORMAD2 is expressed in nearly 10% of Chinese Han lung cancer tissues, which is a new target for lung cancer research ([@B48]). Lipoma preferred partner (LPP) may be an important candidate molecular marker for the classification of NSCLC tissue subtypes. PTPN3 can inhibit lung cancer by regulating EGFR signal ([@B45]). However, there are no reports of KLHL3 in lung cancer, which also suggests a new idea of candidate molecular markers for the identification of lung cancer subtypes.

The Relationship Between Methylation and Expression Signature Genes {#S3.SS4}
-------------------------------------------------------------------

The 113 methylation features can be mapped onto 93 genes. We overlapped the selected methylation feature genes and expression feature genes and found that HNF1B and TP63 were dysfunctional on both methylation and gene expression levels. HNF1B was one of the DNA methylated markers of the same subtype ([@B54]; [@B64]). TP63, also known as P63, was considered to be the most common marker for SCLC ([@B6]; [@B76]).

We downloaded the 66 lung cancer genes from KEGG hsa05223 NSCLC^[4](#footnote4){ref-type="fn"}^ and mapped them and the overlapped two genes: HNF1B and TP63, onto STRING network ([@B72]). TP63 interacted with 39 KEGG lung cancer genes: AKT1, AKT3, ALK, BAK1, BAX, CASP9, CCND1, CDK4, CDK6, CDKN1A, CDKN2A, DDB2, E2F1, E2F2, E2F3, EGF, EGFR, EML4, ERBB2, FHIT, FOXO3, GADD45A, GRB2, HRAS, KRAS, MAP2K1, MAPK1, MAPK3, NRAS, PIK3CA, PIK3CB, PIK3R1, RB1, STAT3, STAT5A, STAT5B, STK4, TGFA, and TP53. HNF1B interacted with 14 KEGG lung cancer genes: AKT1, AKT2, CCND1, CDKN1A, CDKN2A, EGF, HRAS, KRAS, MAPK1, MAPK3, PIK3CA, RXRA, STAT3, and TP53.

What's more, we searched the methylation genes and expression genes in STRING database ([@B72]) and extracted the experimentally determined interaction and plotted the network in [Figure 3](#F3){ref-type="fig"}. The light-yellow nodes were methylation genes, the light-blue nodes were expression genes. The overlapped methylation and expression genes were marked in red, the overlapped methylation and CNV genes from [@B42] were marked in pink. It can be seen that TP63 played an important role in connecting methylation genes and expression genes. The methylation genes and expression genes were closely connected to form a dense functional module on the network.

![The methylation genes and expression genes with experimentally determined interactions on STRING network. The light-yellow nodes were methylation genes, and the light-blue nodes were expression genes. The overlapped methylation and expression genes were marked in red, and the overlapped methylation and CNV genes were marked in pink. TP63 played an important role in connecting methylation genes and expression genes.](fbioe-08-00003-g003){#F3}

The Biological Significance of the Identified Signature {#S3.SS5}
-------------------------------------------------------

To develop more specific and individualized targeted therapy, there is an urgent need to improve our knowledge on the molecular basis, in addition to different phenotypes. It is noteworthy that adenocarcinoma and squamous cell carcinoma show marked differences in expression profiles, DNA methylation, and lesion location. In this study, the features containing methylation and expression data were screened by Boruta and then further sorted by MCFS. After comparing the selected features with related literatures, a certain correlation was found between these features and lung cancer subtypes.

In this study, 113 methylation features were screened and mapped to 93 genes. We inquired about the functions of these genes and their relationship with lung cancer to discuss whether they have the potential as molecular markers to recognize LUAD and SQCLC. Many genes have been proved to promote or inhibit the progression of lung cancer. For instance, FOXK1 was expressed in many malignant tissues ([@B28]) and [@B52] also found that FOXK1 plays a carcinogenic role in lung cancer. MAD1L1 is a checkpoint gene, with its mutation been proved to play a pathogenic role in lung cancer ([@B75]). Some genes have been reported to be related with the prognosis of NSCLC, such as HORMAD2 and ANO1. The overexpression of ANO1 is related to the high expression of EGFR, which can be used as a predictor of recurrence after NSCLC ([@B25]). In addition, according to [@B83] HORMAD2 gene polymorphism has great potential prognostic value in Chinese patients with NSCLC. Other genes are associated with NSCLC subtypes, such as another member of the FOX family, FOXK2, which was reported to be closely related to the overall survival of LUAD ([@B15]). DOK1 and HOPX were found to serve as lung tumor suppressors for LUAD ([@B4]; [@B16]). In the study of [@B84] the methylation locus of PARD3 gene was positively correlated with the expression of PARD3 and suppression of PARD3 intensified chemoresistance in LUAD cells. SFTA3 was found obviously overexpressed in LUAD, and its expression in LUAD and SQCLC was quite different. Therefore, the sensitivity and specificity of using SFTA3 to distinguish the two subtypes will be relatively high ([@B82]). ARHGEF1 aliased p114RhoGEF and its expression might help to predict progression and survival of SQCLC patients ([@B68]). Notably, LPP has multiple functions of actin binding protein and transcriptional coactivator ([@B38]). [@B57] proved that the expression of LPP reduces the number of circulating tumor cells and inhibits lung cancer metastasis. [@B33] used high-resolution array-CGH to find that the difference in genomic imbalance patterns between SQCLC and LUAD was most significant in 3q26.2-q29, while LPP (3q28) was significantly targeted in SQCLC, suggesting that LPP may be an attractive candidate molecular marker for histological subtype classification of NSCLC and may be involved in the pathogenesis of SQCLC.

We also investigated 23 expressed genes in lung cancer, and found that many studies clearly indicated that some genes were associated with LUAD or SQCLC. DSC3 ([@B23]; [@B51]) and KRT5 ([@B81]; [@B74]) have been proved to be an effective marker of SQCLC. ANXA8 ([@B11]) and DSG3 ([@B63]) were significantly over-expressed in SQCLC, and DSG3 could be an effective ancillary marker to identify SQCLC ([@B62]; [@B22]). VSNL1, also known as VILIP-1, was a tumor suppressor gene specific to SQCLC ([@B20]). KRT6A, KRT6B, and KRT6C, members of the keratin protein family, are specific to squamous cells and associated with epidermis of squamous epithelium ([@B21]; [@B24]; [@B10]). In addition, we also identified several genes primarily associated with LUAD. According to [@B2] RORC is a specific transcription factor in the tumor area of lung tissue in patients with LUAD. DLX5 ([@B35]; [@B2]), MUC1 ([@B53]; [@B56]), and KRT17 ([@B19]; [@B47]) were found to be overexpressed in LUAD.

The GO Enrichment Analysis of the Identified Signature {#S3.SS6}
------------------------------------------------------

In order to further analyze the relationship between mixed characteristics and lung cancer, we carried out GO enrichment analysis. The results suggest that characteristic genes are mainly related to keratinization, epidermal cell differentiation, tissue development, and cytoplasm. The GO enriched results with FDR (False Discovery Rate) smaller than 0.05 are listed in [Table 5](#T5){ref-type="table"}. P63 appears to be useful in differentiating SQCLC from LUAD in small biopsies with no keratosis or glandular differentiation, helping to establish different treatments ([@B9]). The expression of keratinocyte transglutaminase and cytokeratin 10 was measured as markers of squamous differentiation ([@B49]). Epidermal cell differentiation is related to EGFR signal pathway, which can inhibit the proliferation and metastasis of cancer cells, while EGFR mutation is largely limited to LUAD ([@B40]). The expression of Promyelocytic leukemia zinc finger (PLZF) in SQCLC was weak or absent, which was significantly lower than that in LUAD ([@B80]).

###### 

The GO enrichment results of the identified signature.

  **GO Term**                                  **FDR**    ***P* value**   **Number of overlapped genes**
  -------------------------------------------- ---------- --------------- --------------------------------
  GO:0070268 cornification                     8.58E-05   5.39E-09        9
  GO:0009913 epidermal cell differentiation    0.0109     1.42E-06        11
  GO:0031424 keratinization                    0.0109     2.05E-06        9
  GO:0030216 keratinocyte differentiation      0.0109     2.73E-06        10
  GO:0060429 epithelium development            0.0115     3.59E-06        20
  GO:0030855 epithelial cell differentiation   0.0130     4.91E-06        15
  GO:0043588 skin development                  0.0172     7.57E-06        11
  GO:0009888 tissue development                0.0202     1.01E-05        25
  GO:0008544 epidermis development             0.0319     1.80E-05        11
  GO:0005737 cytoplasm                         0.0045     2.34E-06        79
  GO:0005829 cytosol                           0.0083     8.55E-06        46

To sum up, most of the 113 methylated genes and 23 expressed genes we found are closely related to lung cancer, and some of them have the possibility of distinguishing SQCLC from LUAD, which is helpful for the targeted selection of lung cancer treatment and provide more research support for lung cancer molecular markers.
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###### 

The annotations of the 113 methylation features.

###### 

Click here for additional data file.
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